Form 4 for TDOC Teladoc Health, Inc.
Accepted 2026-03-03 00:00:00 ET · period of report 2022-02-27 · accession 0001347535-26-000002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-03-03 | 2022-02-27+ | TDOC | DIVITA CHARLES III | CEO, Dir | M - OptEx | — | +177.0K | 370.1K | +92% | — |
| D | 2026-03-03 | 2026-03-02 | TDOC | DIVITA CHARLES III | CEO, Dir | S - Sale+OE | $5.12 | -50.1K | 327.9K | -13% | -$256.7K |
| DM | 2026-03-03 | 2026-02-27+ | TDOC | DIVITA CHARLES III | CEO, Dir | A - Grant | $0.00 | +715.6K | 23.6K | New | $0 |
| DM | 2026-03-03 | 2026-02-27 | TDOC | DIVITA CHARLES III | CEO, Dir | M - OptEx | $0.00 | -177.0K | 338.2K | -34% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-27 | M | A | 7,864 | — | 378,007 | D | — | — | (F2) Performance stock units convert to shares of TDOC common stock on a one-for-one basis. |
| 2 | Common | Common Stock | 2026-03-02 | S | D | 50,145 | $5.12 | 327,862 | D | — | — | (F3) Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance stock unit and restricted stock unit awards. |
| 3 | Common | Common Stock | 2022-02-27 | M | A | 169,107 | — | 370,143 | D | — | — | (F1) Restricted stock units convert to shares of TDOC common stock on a one-for-one basis. |
| 4 | Derivative | Restricted Stock Units | 2026-03-01 | A | A | 692,041 | $0.00 | 692,041 | D | — · — to — | 692,041 Common Stock | (F9) Each restricted stock unit represents a contingent right to receive one share of TDOC common stock. (F10) One-third of the restricted stock units vest on the first anniversary of the grant date, with the remainder vesting in eight substantially equal quarterly installments thereafter. |
| 5 | Derivative | Performance Stock Units | 2026-02-27 | A | A | 23,591 | $0.00 | 23,591 | D | — · — to — | 23,591 Common Stock | (F6) Performance award amount determined based on metrics in respect of the issuer's 2025 financial results. (F5) Each performance stock unit represents a contingent right to receive one share of TDOC common stock. (F7) The performance stock units vest as to one-third on March 1, 2026, with the remainder vesting in eight substantially equal quarterly installments thereafter. |
| 6 | Derivative | Performance Stock Units | 2026-02-27 | M | D | 7,864 | $0.00 | 15,727 | D | — · — to — | 7,864 Common Stock | (F2) Performance stock units convert to shares of TDOC common stock on a one-for-one basis. (F8) On March 1, 2026, the reporting person earned 23,591 performance stock units, vesting one-third on March 1, 2026, with the remainder vesting in eight substantially equal quarterly installments thereafter. |
| 7 | Derivative | Restricted Stock Units | 2026-02-27 | M | D | 169,107 | $0.00 | 338,215 | D | — · — to — | 169,107 Common Stock | (F1) Restricted stock units convert to shares of TDOC common stock on a one-for-one basis. (F4) On March 1, 2025, the reporting person was granted 507,322 restricted stock units, vesting one-third on March 1, 2026, with the remainder vesting in eight substantially equal quarterly installments thereafter. The reporting person's previous Form 4 filing incorrectly listed the number of restricted stock units granted as 507,332 instead of 507,322 due to a typo which has been corrected in this Form 4. |